Sera Prognostics Appoints Scott Gleason CFO
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 […]
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.
Sera Prognostics Announces Pricing of $50 Million Public Offering
Sera Prognostics Announces Pricing of $50 Million Public Offering
SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES
SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES
